BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 348315)

  • 1. Phase II evaluation of pyrazofurin in patients with carcinoma of the lung.
    Gralla RJ; Currie VE; Wittes RE; Golbey RB; Young CW
    Cancer Treat Rep; 1978 Mar; 62(3):451-2. PubMed ID: 348315
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II evaluation of pyrazofurin in patients with advanced colorectal carcinoma.
    Carroll DS; Kemeny NE; Gralla RJ
    Cancer Treat Rep; 1979 Jan; 63(1):139-40. PubMed ID: 369686
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II trial of pyrazofurin in advanced head and neck cancer.
    Cheng E; Currie V; Wittes RE
    Cancer Treat Rep; 1979; 63(11-12):2047-8. PubMed ID: 526937
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
    Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
    Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study on DON in patients with previously treated advanced lung cancer.
    Eagan RT; Frytak S; Nichols WC; Creagan ET; Ingle JN
    Cancer Treat Rep; 1982 Aug; 66(8):1665-6. PubMed ID: 6286122
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II study of pyrazofurin in advanced colorectal carcinoma.
    Creagan ET; Rubin J; Moertel CG; Schutt AJ; O'connell MJ; Hahn RG; Reitemeir RJ; Frytak S
    Cancer Treat Rep; 1977; 61(3):491-3. PubMed ID: 872147
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I study of pyrazofurin in refractory acute myelogenous leukemia.
    Vogler WR; Trulock PD
    Cancer Treat Rep; 1978 Oct; 62(10):1569-71. PubMed ID: 152146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of pyrazofurin in malignant melanoma.
    Budman D; Currie V; Wittes R
    Cancer Treat Rep; 1977 Dec; 61(9):1733-4. PubMed ID: 340040
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of advanced non-small cell lung cancer with bisantrene.
    Fuks JZ; Van Echo DA; Garbino C; Kasdorf H; Aisner J
    Cancer Treat Rep; 1983 Jun; 67(6):597-8. PubMed ID: 6305499
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
    Nichols WC; Kvols LK; Ingle JN; Edmonson JH; Ahmann DL; Rubin J; O'Connell MJ
    Cancer Treat Rep; 1978 May; 62(5):837-9. PubMed ID: 657166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of tiazofurin in recurrent squamous cell carcinoma of the head and neck.
    Dimery IW; Neidhart JA; McCarthy K; Krakoff IH; Hong WK
    Cancer Treat Rep; 1987 Apr; 71(4):425-6. PubMed ID: 3548960
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II evaluation of pyrazofurin in patients with metastatic sarcoma.
    Gralla RJ; Sordillo PP; Magill GB
    Cancer Treat Rep; 1978 Oct; 62(10):1573-4. PubMed ID: 361228
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical trial of weekly pyrazofurin.
    Cummings FJ; Stoller RG; Calabresi P
    Cancer Treat Rep; 1979 Aug; 63(8):1363-5. PubMed ID: 157807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of acivicin in advanced breast carcinoma: a Cancer and Leukemia Group B Study.
    Booth BW; Korzun AH; Weiss RB; Ellison RR; Budman D; Khojasteh A; Wood W
    Cancer Treat Rep; 1986 Oct; 70(10):1247-8. PubMed ID: 3530455
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of aclarubicin in epidermoid carcinoma of the head and neck.
    Carugati AA; Olivari AJ; Campos DM; Pradier R; Woolley PV
    Cancer Treat Rep; 1986 Jun; 70(6):799-800. PubMed ID: 3524828
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II evaluation of bisantrene in patients with renal cell carcinoma.
    Myers JW; Von Hoff DD; Coltman CA; Kuhn JG; Van Echo D; Rivkin S; Pocelinko R
    Cancer Treat Rep; 1982 Oct; 66(10):1869-71. PubMed ID: 7127326
    [No Abstract]   [Full Text] [Related]  

  • 17. [Phase II study of KW2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with carcinoma of the lung and metastatic pulmonary tumor].
    Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Shibuya M; Shimabukuro Z
    Gan To Kagaku Ryoho; 1983 Mar; 10(3):834-9. PubMed ID: 6882001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of AMSA in patients with metastatic lung cancer.
    Nichols WC; Eagan RT; Frytak S; Ingle JN; Creagan ET; Kvols LK
    Cancer Treat Rep; 1980; 64(12):1383-5. PubMed ID: 6894104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of pyrazofurin in patients with multiple myeloma refractory to standard cytotoxic therapy.
    Lake-Lewin D; Myers J; Lee BJ; Young CW
    Cancer Treat Rep; 1979 Aug; 63(8):1403-4. PubMed ID: 476714
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
    Myers JW; Von Hoff DD; Clark GM; Coltman CA
    Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.